ReviewCurrent atherosclerosis reports2023
Atherosclerosis in Systemic Lupus Erythematosus.
Review in Current atherosclerosis reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 19 citations in OpenAlex.
- Belimumab prevention against organ damage over 8 years and safety up to 13 years: three pooled open-label, long-term extension SLE studies.Lupus science & medicine · 2026Article
- Cardiovascular Risks in Autoimmune and Inflammatory Diseases.Journal of clinical medicine · 2026Article
- IL-6 in Systemic Lupus Erythematosus: At the Intersection of Disease Activity and Cardiovascular Risk.Journal of clinical medicine · 2026Article
- Cardiometabolic risk and vascular changes in rheumatic diseases.Rheumatology international · 2026Review
- Cardiovascular Disorders in Systemic Lupus Erythematosus.Current vascular pharmacology · 2026Review
- Systemic lupus erythematosus-accelerated atherosclerosis: mechanistic insights and clinical implications.Frontiers in immunology · 2026Review
- Trained Immunity and Cardiovascular Risk: An Immunological Perspective.Immunological reviews · 2026Review
- Association Between Cardiovascular Risk and Subclinical Atherosclerosis in Korean Female Patients with Systemic Lupus Erythematosus.Journal of clinical medicine · 2025Article
- Pathophysiological Links Between Inflammatory Bowel Disease and Cardiovascular Disease: The Role of Dysbiosis and Emerging Biomarkers.Biomedicines · 2025Review
- Thromboembolic Episodes in Patients with Systemic Lupus Erythematosus Without Atrial Fibrillation/Atrial Flutter Are Related to the Presence of at Least 3 Points in the CHAJournal of clinical medicine · 2025Article
- Causal correlations between inflammatory proteins and heart failure: A two-sample Mendelian randomization analysis.ESC heart failure · 2025Article
- Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment.Rheumatology (Oxford, England) · 2025Article
- Seven-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls.Rheumatology (Oxford, England) · 2025Article
- Neutrophil-to-lymphocyte ratio and CD40 as diagnostic biomarkers for systemic lupus erythematosus and its disease activity.American journal of translational research · 2025Article
- Emerging Imaging Techniques for Atherosclerosis in Systemic Immune-Mediated Inflammatory Conditions.Arteriosclerosis, thrombosis, and vascular biology · 2025Review
- Efficacy of Diagnostic Testing of Suspected Coronary Artery Disease: A Contemporary Review.Cardiology · 2025Review
- Neutrophil diversity and function in health and disease.Signal transduction and targeted therapy · 2024Review
- Cardiac MRI in Rheumatic Disease.Rheumatic diseases clinics of North America · 2024Review
- Biomarkers in Systemic Lupus Erythematosus along with Metabolic Syndrome.Journal of clinical medicine · 2024Review
- Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement.Journal of the American College of Cardiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewSystemic lupus erythematosus (SLE) patients are at increased risk of cardiovascular disease (CVD) compared to the general population, despite most patients being young females, who are not classically considered to be at high risk for cardiovascular disease using traditional risk assessment tools. The purpose of this review is to discuss the pathophysiology of atherosclerosis in SLE and raise awareness of the relationship between SLE and CVD. RECENT
findingsThe increased risk of CVD in SLE patients is multifactorial, due to proatherogenic lipid profiles, immune dysregulation and inflammation, side effects of lupus treatment, and microvascular dysfunction. Conventional CV risk models often underperform in the identification of SLE patients at high risk of atherosclerosis. The use of non-invasive imaging serves as a strategy to identify patients with evidence of subclinical CVD and in the evaluation of symptomatic patients. Identification of subclinical atherosclerosis allows for aggressive management of CV risk factors. SLE patients experience an increased risk of atherosclerotic CVD, which is not solely explained by traditional CV risk factors. It is imperative that clinicians are aware of this association to implement prompt detection and treatment of atherosclerotic CVD in SLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.